IL6 and systemic sclerosis: Interestingly, we found that a tissue gene expression signature corresponding to plasma cells in skin and lung was associated with prognosis in SSc and demonstrated a pharmacodynamic response to tocilizumab treatment (88), suggesting that IL6 modulation of adaptive immunity may also contribute to SSc pathogenesis.